Evidence map›Paper›PMID 30485898›Full record

ArticleRevista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia2018

Methotrexate Therapy for Ectopic Pregnancies: A Tertiary Center Experience.

Ozgur Ozyuncu, Atakan Tanacan, Sinem Ayse Duru, Mehmet Sinan Beksac

Open access · diamondAbstract read
In one paragraph

Article in Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Largest Tubal Pregnancy: 14th Week.Case reports in obstetrics and gynecology · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ozgur OzyuncuDivision of Perinatology, Department of Obstetrics and Gynecology, Faculty of Medicine at Hacettepe University, Ankara, Turkey.
Atakan TanacanDivision of Perinatology, Department of Obstetrics and Gynecology, Faculty of Medicine at Hacettepe University, Ankara, Turkey.
Sinem Ayse DuruDivision of Perinatology, Department of Obstetrics and Gynecology, Faculty of Medicine at Hacettepe University, Ankara, Turkey.
Mehmet Sinan BeksacDivision of Perinatology, Department of Obstetrics and Gynecology, Faculty of Medicine at Hacettepe University, Ankara, Turkey.
Hacettepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOur aim is to demonstrate the importance of methotrexate (MTX) therapy for the treatment of ectopic pregnancy (EP).

methodsThis retrospective study consisted of 99 patients (72 tubal EPs, 20 pregnancies of unknown location (PUL), 4 cesarean section (CS) scar EPs and 3 cervical EPs) treated with MTX.

resultsMethotrexate therapy was successful in 68.5% of EPs. There were statistically significant differences between the MTX success and failure groups based on ultrasonographic findings, patient complaints, gestational week and serum human chorionic gonadotropin (hCG) values. The MTX success rates in PUL and tubal pregnancies were 95% and 61.1%, respectively. The MTX success rates in single-dose, two-dose and multi-dose protocol groups were 86.9%, 28.6% and 40%, respectively. All cervical and CS scar ectopic pregnancies were treated successfully with MTX therapy.

conclusionMethotrexate might be the first-line treatment option for EPs under certain conditions. Physicians must be more cautious in cases with higher hCG values, the presence of abdominal-pelvic pain, the presence of fetal cardiac activity, larger gestational sac (GS) diameters, and more advanced gestational weeks according to the last menstrual period.

Indexed as

Abortifacient Agents, NonsteroidalAdultFemaleHumansMethotrexatePregnancyPregnancy, EctopicRetrospective StudiesTreatment OutcomeAbortifacient Agents, NonsteroidalMethotrexate

Identifiers

PMID30485898
PMCPMC10316905
OpenAlexW2902020495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.